List of Excipients in Branded Drug LYNPARZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	LYNPARZA	olaparib	0310-0668	COPOVIDONE K25-31	2029-10-07
AstraZeneca Pharmaceuticals LP	LYNPARZA	olaparib	0310-0668	FERRIC OXIDE YELLOW	2029-10-07
AstraZeneca Pharmaceuticals LP	LYNPARZA	olaparib	0310-0668	FERROSOFERRIC OXIDE	2029-10-07
AstraZeneca Pharmaceuticals LP	LYNPARZA	olaparib	0310-0668	HYPROMELLOSE	2029-10-07
AstraZeneca Pharmaceuticals LP	LYNPARZA	olaparib	0310-0668	MANNITOL	2029-10-07
AstraZeneca Pharmaceuticals LP	LYNPARZA	olaparib	0310-0668	POLYETHYLENE GLYCOL 400	2029-10-07

Lynparza Excipient Strategy and Commercial Opportunities for Olaparib

Last updated: September 1, 2026

Lynparza (olaparib) is an oral PARP inhibitor marketed by AstraZeneca and Merck & Co. Its commercial formulation is a conventional immediate-release film-coated tablet, with legacy capsule presentations no longer central to current U.S. prescribing. The strongest excipient opportunities are in generic-equivalent tablets, lactose-free or low-moisture formulations, direct-compression platforms, coating systems, and differentiated dosage forms that can meet FDA bioequivalence requirements without relying on AstraZeneca’s formulation architecture.

What excipients are used in Lynparza tablets?

Lynparza tablets use a standard oral solid dosage formulation built around lactose, hypromellose, crospovidone, colloidal silicon dioxide, and sodium stearyl fumarate. The tablets are film-coated with hypromellose, titanium dioxide, triacetin, and iron oxides.

Lynparza attribute	Current commercial description
Active ingredient	Olaparib
Dosage form	Immediate-release film-coated tablet
U.S. strengths	100 mg and 150 mg
Typical adult dose	300 mg twice daily, administered as two 150 mg tablets
Older presentation	50 mg hard capsule
Route	Oral
Food instructions	May be taken with or without food
U.S. NDA	NDA 208558
Primary sponsor	AstraZeneca
Co-commercialization	Merck & Co. in selected oncology indications
Key excipient functions	Dilution, binding, disintegration, glidancy, lubrication, film coating

The U.S. prescribing information identifies inactive ingredients but does not disclose quantitative excipient levels. That limits direct replication and increases the value of formulation development, powder characterization, and comparative dissolution work.[1]

What is the likely function of each Lynparza excipient?

Excipient	Likely formulation role	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Creates a lactose-intolerance and lactose-free opportunity
Hypromellose	Binder and film-forming polymer	Supports tablet strength and coating performance
Crospovidone	Superdisintegrant	Helps achieve rapid tablet breakup
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and manufacturing consistency
Sodium stearyl fumarate	Lubricant	May reduce over-lubrication risk relative to magnesium stearate
Titanium dioxide	Opacifier and pigment	Relevant to coating substitutions and regional regulatory requirements
Triacetin	Plasticizer	Supports flexible film formation
Iron oxides	Colorants	Enable strength differentiation and product identification

The excipient system is commercially conservative. It does not indicate a modified-release mechanism, lipid-based delivery system, enteric protection, or complex solubility-enhancement technology.

What formulations are protected by Lynparza-related intellectual property?

Lynparza’s principal commercial protection has historically centered on olaparib composition-of-matter, therapeutic use, crystalline or solid-state forms, and dosage-form or treatment patents. Excipient selection alone is unlikely to provide the primary barrier to generic entry.

A generic applicant would normally seek approval through an abbreviated new drug application and demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. It could use different inactive ingredients if the finished product meets applicable FDA requirements and does not create safety, quality, or bioequivalence problems.

The commercial implication is direct: an excipient supplier that offers a substitute for one ingredient does not automatically create freedom to operate. The value lies in enabling a complete non-infringing formulation with equivalent performance.

Where can excipient patents create value?

Potentially valuable claim types include:

• A defined olaparib composition with specified excipient classes or concentration ranges.
• A low-moisture or moisture-stabilized olaparib tablet.
• A formulation with improved dissolution after storage.
• A lactose-free or sugar-free tablet with comparable bioavailability.
• A tablet manufactured by direct compression rather than granulation.
• A specific coating system that improves stability, swallowability, or identification.
• A particle-size and excipient combination that controls content uniformity.
• A pediatric or geriatric dosage form, if supported by clinical and regulatory requirements.
• A manufacturing process that reduces degradation, sticking, segregation, or compression defects.

Patent value depends on claim scope, priority date, validity, written description, enablement, and the ability to detect infringement. Broad claims covering conventional lactose, hypromellose, and crospovidone combinations are likely to face validity and obviousness pressure. Narrow claims tied to measurable performance or a technically demonstrated stability benefit may have greater durability.

How strong is the Lynparza patent estate?

Lynparza has had a substantial branded patent estate because olaparib is a targeted oncology product with multiple approved indications and a long clinical-development history. The estate should be separated into four categories:

Patent category	Relevance to olaparib competition	Commercial assessment
Compound patents	Protect olaparib itself	Usually the strongest early barrier
Solid-state or crystalline-form patents	May constrain API manufacture and sourcing	Important for API suppliers and generics
Method-of-use patents	Cover selected cancers, biomarker populations, or combinations	Relevant to labeling and induced-infringement risk
Formulation and manufacturing patents	Cover dosage forms, processes, or stability attributes	Relevant to excipient strategy and ANDA design

The expiry date for a particular U.S. olaparib patent cannot be reduced to the date of the original compound patent. Patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and later-issued formulation or method patents can change the effective commercial position. The controlling source for approved-product patent listings is the FDA Orange Book, which should be reviewed by patent number and expiration date before a launch or licensing decision.[2]

When does Lynparza lose exclusivity?

Lynparza’s commercial exclusivity has several layers:

Exclusivity layer	Effect on competition
New chemical entity exclusivity	Delayed ANDA approval during the statutory period
Orphan-drug exclusivity	May restrict approval for the same disease or indication
Patent exclusivity	May block approval, launch, or labeled use through listed claims
Pediatric exclusivity	Can add six months to qualifying regulatory exclusivities
Regulatory data protections	May limit certain reliance pathways depending on product and jurisdiction

The original U.S. approval was for olaparib capsules in December 2014. The tablet formulation was approved later, and the current 100 mg and 150 mg tablet presentation became the principal commercial form.[1] FDA regulatory exclusivity does not necessarily end at the same time as patent protection. Generic entry therefore depends on the Orange Book patent position, Paragraph IV litigation, settlements, and the commercial strategy of individual ANDA sponsors.

What is the Orange Book status of Lynparza?

The Orange Book lists patents that the NDA holder has submitted as covering the drug substance, drug product, or approved methods of use. A listed patent can require an ANDA applicant to make one of four certifications:

1. No relevant patent information has been submitted.
2. The patent has expired.
3. The applicant will not market before patent expiration.
4. The patent is invalid, unenforceable, or will not be infringed.

The fourth certification is the Paragraph IV pathway. It can trigger patent litigation if the NDA holder sues within the statutory period after receiving the certification notice. A lawsuit can impose a 30-month stay on final FDA approval, subject to statutory exceptions and court action.[3]

For Lynparza, the commercial review should examine:

• Drug-substance patents for olaparib.
• Drug-product patents covering tablets or capsules.
• Method-of-use patents for ovarian, breast, pancreatic, prostate, and other approved cancers.
• Patent expiration dates after patent-term adjustment.
• Any pediatric exclusivity attached to the listed patents.
• Whether an ANDA applicant seeks approval for all indications or uses a section viii statement to omit protected methods.

Which companies are challenging Lynparza?

Publicly reported generic activity should be tracked through FDA ANDA disclosures where available, Paragraph IV notice litigation, district-court dockets, and the Orange Book patent dispute records. A company may prepare an olaparib generic without publicly disclosing its development program until litigation, approval, or launch activity becomes visible.

The absence of a public lawsuit does not establish the absence of a generic challenge. Generic companies can wait for patent expiry, file a Paragraph IV certification without immediate litigation, pursue a limited label, or delay commercial launch under a settlement agreement.

What excipient strategy is best for an olaparib generic?

The highest-probability strategy is a robust immediate-release tablet that matches the reference product’s performance without copying its qualitative or quantitative composition.

1. Use a direct-compression or low-shear platform

A direct-compression formulation can reduce processing steps, solvent exposure, and manufacturing cost. The main technical risks are:

• Poor flow at low drug loading.
• Segregation between olaparib and excipients.
• Tablet weight variability.
• Capping or lamination.
• Slow dissolution caused by hydrophobic lubrication.
• Content-uniformity failure.

A co-processed filler-binder, optimized crospovidone grade, and controlled colloidal silica level may improve manufacturability while preserving immediate release.

2. Develop a lactose-free alternative

Lactose is present in the reference tablet according to the FDA label. A lactose-free generic could use mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed excipient system.

The principal commercial benefits are broader patient acceptability and supply-chain flexibility. The technical risks include altered tablet density, hardness, disintegration, dissolution, and powder flow. A lactose-free formulation may also be easier to position for international markets with different excipient preferences.

3. Optimize moisture and chemical stability

Olaparib is an oncology API administered chronically in many approved settings. Stability failures can arise from moisture uptake, API-excipient interactions, coating permeability, or packaging performance.

Useful excipient and packaging strategies include:

• Low-moisture filler systems.
• Desiccant-containing bottles.
• High-barrier blister packaging.
• Controlled water activity during granulation and compression.
• Hypromellose-based coatings with optimized plasticizer levels.
• Excipients with low peroxide and aldehyde impurities.
• Stability-indicating analytical methods for degradation products.

A supplier that can document low reactive impurity profiles and consistent particle-size distribution may have more value than a low-cost commodity excipient supplier.

4. Avoid unnecessary release-rate complexity

The reference product is an immediate-release tablet. A generic applicant generally gains little from introducing sustained release or enteric protection unless it solves a clear clinical or manufacturing problem. Such changes can require additional development, raise bioequivalence risk, and create a new drug-product profile.

The commercial target should be rapid, reproducible dissolution across relevant pH conditions, with no food-related performance problem beyond the reference product’s known profile.

What commercial opportunities exist for excipient suppliers?

Reference-equivalent generic supply

The largest opportunity is supply to generic olaparib developers. The required volumes may be modest compared with high-volume cardiovascular or diabetes products, but oncology products can support higher unit economics and longer customer relationships.

Priority materials include:

• Lactose or lactose-free direct-compression fillers.
• Crospovidone.
• Hypromellose.
• Sodium stearyl fumarate or alternative lubricants.
• Colloidal silicon dioxide.
• Film-coating premixes.
• Low-peroxide and low-aldehyde excipient grades.
• High-barrier packaging components.

Formulation development partnerships

An excipient manufacturer can provide more value through formulation support than through raw-material sales. Relevant services include:

• Design of experiments for excipient screening.
• Powder-flow and compressibility characterization.
• Dissolution benchmarking against Lynparza.
• API-excipient compatibility testing.
• Stability studies under ICH conditions.
• Scale-up from laboratory compression to commercial tooling.
• Documentation packages for FDA and international submissions.

Specialty differentiated products

Potential longer-term opportunities include:

• Lactose-free tablets.
• Smaller tablets with equivalent dose delivery.
• Orally disintegrating tablets.
• Sprinkleable dosage forms.
• Flexible packaging for oncology adherence programs.
• Regional formulations that remove colorants or titanium dioxide.
• Dose-flexible products for patients requiring reductions because of adverse reactions or concomitant CYP3A inhibitors.

These products may require a new drug application, a supplemental strategy, or a jurisdiction-specific regulatory pathway. They should not be treated as simple generic substitutions.

How does Lynparza compare with competing PARP inhibitors?

Product	Active ingredient	Typical commercial form	Excipient opportunity
Lynparza	Olaparib	Immediate-release tablets; legacy capsules	Generic-equivalent and lactose-free tablet platforms
Rubraca	Rucaparib	Film-coated tablets	Similar oral-solid excipient opportunities
Zejula	Niraparib	Capsules	Capsule-fill, dose-flexibility, and swallowability opportunities
Talzenna	Talazoparib	Capsules	Lower-dose capsule technology and API uniformity
Ojemda-class comparison	Not a PARP inhibitor	Not directly comparable	No direct formulation benchmark

Lynparza has a broad indication footprint and substantial clinical adoption, which may increase generic commercial value. Zejula and other PARP inhibitors differ in strength, dosing, capsule or tablet presentation, metabolism, and indication mix. Excipient platforms should therefore be product-specific rather than marketed as interchangeable PARP-inhibitor technologies.

What generic launch risks exist for Lynparza?

The principal risks are patent timing, API supply, bioequivalence, and oncology-market access.

Risk	Impact
Listed composition or formulation patent	Can delay approval or launch
Method-of-use patent	May require a skinny label or indication carve-out
API solid-state restriction	Can limit qualified API sources
Narrow therapeutic index concerns	May increase scrutiny of exposure and dissolution
High API cost	Can compress generic margins
Low patient volume relative to common generics	May limit manufacturing scale
Brand contracting	Can reduce realized generic price
Multiple generic entrants	Can rapidly erode price after launch
Treatment-specific demand	Makes forecasting more dependent on oncology guidelines

For excipient companies, the practical issue is customer timing. Demand can move from development-scale quantities to commercial supply only after patent and litigation outcomes become clearer. Supply agreements should address forecast volatility, change control, dual sourcing, and regulatory notification obligations.

What licensing deals affect Lynparza’s commercial position?

AstraZeneca and Merck have a global strategic collaboration for Lynparza in selected oncology settings. That arrangement affects commercial control, development economics, and regional commercialization, but it does not create an excipient license for third-party manufacturers.[4]

Excipient suppliers may instead pursue:

• Preferred-supplier agreements with generic developers.
• Formulation-development licenses for proprietary co-processed excipients.
• Technology-transfer arrangements for coating or low-moisture platforms.
• Regional supply agreements tied to ANDA or abbreviated applications.
• Dual-source contracts designed to protect oncology-product continuity.

The most valuable licensing target is usually a formulation technology with measurable performance advantages and defensible patent claims, not a conventional excipient already widely available from multiple suppliers.

Key Takeaways

• Lynparza is an immediate-release olaparib film-coated tablet available primarily in 100 mg and 150 mg strengths.
• The reference formulation uses lactose monohydrate, hypromellose, crospovidone, colloidal silicon dioxide, sodium stearyl fumarate, and conventional coating excipients.
• Quantitative excipient composition is not disclosed in the FDA label, creating formulation-development value.
• The strongest near-term opportunity is a bioequivalent generic tablet, including lactose-free and direct-compression alternatives.
• Excipient suppliers can differentiate through low-reactive-impurity grades, moisture control, co-processed excipients, and formulation services.
• Patent and regulatory barriers are more likely to arise from olaparib composition, solid-state, method-of-use, and listed drug-product patents than from ordinary excipient selection.
• Orange Book review, Paragraph IV litigation, and settlement terms determine the realistic generic launch window.
• A differentiated dosage form would create greater commercial value but would likely require a more demanding regulatory strategy than a conventional ANDA.

FAQs

Can a generic Lynparza use different excipients?

Yes. A generic may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling.

Is Lynparza a lactose-free medicine?

The U.S. Lynparza tablet label identifies lactose monohydrate as an inactive ingredient. A lactose-free alternative would require separate formulation development and regulatory review.

Does Lynparza use a sustained-release excipient system?

No. The marketed tablet is an immediate-release formulation. Its excipients support compression, disintegration, lubrication, and film coating rather than controlled release.

Which excipient is most important for Lynparza dissolution?

Crospovidone is the primary disintegration-related excipient identified in the label. Dissolution also depends on olaparib particle size, tablet porosity, lubricant level, compression force, and the complete excipient system.

Can an excipient patent block a generic olaparib launch?

Yes, if a valid, enforceable patent claims the generic formulation or manufacturing process and the generic product falls within the claims. Conventional excipient use alone is less likely to create a durable barrier than a narrowly defined formulation with demonstrated stability or dissolution performance.

References

1. U.S. Food and Drug Administration. (2024). Lynparza (olaparib) tablets, prescribing information. AstraZeneca Pharmaceuticals LP. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs

4. Merck & Co., Inc. (2017). Merck and AstraZeneca enter global strategic oncology collaboration. https://www.merck.com/news/ lodestone/